Jessica L. Fetterman, PhD
Assistant Professor, Medicine
Biography
Jessica L. Fetterman, PhD, FAHA is a basic and translational scientist studying the intersections of mitochondrial physiology, mitochondrial genetic epidemiology, and cardiovascular disease. Her work focuses on the contribution of mitochondrial genetic variation and abnormalities to cardiovascular disease in the presence of risk factors, including tobacco product use and diabetes.
Using bioinformatics methods, Dr. Fetterman discovered that several select mitochondrial genetic variants are associated with non-invasive measures of vascular function within the Framingham Heart Study (FHS). Additionally, she has applied similar methodology to select mitochondrial single variant data within Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) to determine the associations of select mitochondrial genetic variants with cardiometabolic measures in collaboration with members of the mitochondrial genetics working group. Recently, Dr. Fetterman was awarded the competitive Trans-Omics Precision Medicine (TOPMed) Analytical Support Award for early career investigators to perform comprehensive bioinformatic annotation of the mitochondrial genetic variants within the TOPMed cohorts.
Dr. Fetterman also conducts research on the impact of new and emerging tobacco products on the vasculature, particularly studies designed to inform tobacco product regulation. Some of her recent work demonstrated that tobacco product flavoring additives induce vascular endothelial dysfunction, an early indicator of cardiovascular injury. She serves as an Associate Director of Education and Training within American Heart Association Tobacco Regulation and Addiction Center. Additionally, she is the Director for the Boston University Tobacco Regulatory Science Affinity Research Collaborative, which is designed to bring together multi-disciplinary teams of scientists within Boston University to increase our understanding of tobacco product use patterns and the impact of new and emerging tobacco products on human health and disease.
Other Positions
- Investigator, Framingham Heart Study
- Member, Whitaker Cardiovascular Institute, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
Education
- University of Alabama at Birmingham, PhD
- Ohio Wesleyan University, BA
Publications
- Published on 8/26/2024
Wu J, Fetterman JL, Cornacchione Ross J, Hong T. Quitting on TikTok: Effects of Message Themes, Frames, and Sources on Engagement with Vaping Cessation Videos. J Health Commun. 2024 Sep; 29(9):590-601. PMID: 39186489.
Read at: PubMed - Published on 7/20/2024
Eckhardt CM, Balte P, Morris JE, Bhatt SP, Couper D, Fetterman J, Freedman N, Jacobs DR, Hou L, Kalhan R, Liu Y, Loehr L, Lutsey PL, Schwartz JE, White W, Yende S, London SJ, Sanchez TR, Oelsner EC. Non-cigarette tobacco products, aryl-hydrocarbon receptor repressor gene methylation and smoking-related health outcomes. Thorax. 2024 Jul 20. PMID: 39033027.
Read at: PubMed - Published on 5/14/2024
Wu J, Benjamin EJ, Ross JC, Fetterman JL, Hong T. Health Messaging Strategies for Vaping Prevention and Cessation Among Youth and Young Adults: A Systematic Review. Health Commun. 2024 May 14; 1-19. PMID: 38742648.
Read at: PubMed - Published on 4/25/2024
Smith KK, Moreira JD, Wilson CR, Padera JO, Lamason AN, Xue L, Gopal DM, Flynn DB, Fetterman JL. A systematic review on the biochemical threshold of mitochondrial genetic variants. Genome Res. 2024 Apr 25; 34(3):341-365. PMID: 38627095.
Read at: PubMed - Published on 2/28/2024
Ranker LR, Wu J, Hong T, Wijaya D, Benjamin EJ, Bhatnagar A, Robertson RM, Fetterman JL, Xuan Z. Social media use, brand engagement, and tobacco product initiation among youth: Evidence from a prospective cohort study. Addict Behav. 2024 Jul; 154:108000. PMID: 38461745.
Read at: PubMed - Published on 11/28/2023
Vargees C, Stroup AM, Niznik T, Dunn D, Wyatt R, Hoetger C, Taleb ZB, Cohn AM, Cobb CO, Fetterman JL. Patterns of use, perceptions, and cardiopulmonary health risks of cigar products: a systematic review. BMC Public Health. 2023 Nov 28; 23(1):2357. PMID: 38017396.
Read at: PubMed - Published on 11/16/2023
Moreira JD, Smith KK, Zilber S, Woleben K, Fetterman JL. Teamwork makes the dream work: functional collaborations between families, scientists, and healthcare providers to drive progress in the treatment of Leigh Syndrome. Orphanet J Rare Dis. 2023 Nov 16; 18(1):355. PMID: 37974220.
Read at: PubMed - Published on 7/17/2023
Rose JJ, Krishnan-Sarin S, Exil VJ, Hamburg NM, Fetterman JL, Ichinose F, Perez-Pinzon MA, Rezk-Hanna M, Williamson E. Cardiopulmonary Impact of Electronic Cigarettes and Vaping Products: A Scientific Statement From the American Heart Association. Circulation. 2023 Aug 22; 148(8):703-728. PMID: 37458106.
Read at: PubMed - Published on 6/29/2023
Brant LCC, Ribeiro AH, Pinto-Filho MM, Kornej J, Preis SR, Fetterman JL, Eromosele OB, Magnani JW, Murabito JM, Larson MG, Benjamin EJ, Ribeiro ALP, Lin H. Association Between Electrocardiographic Age and Cardiovascular Events in Community Settings: The Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2023 Jul; 16(7):e009821. PMID: 37381910.
Read at: PubMed - Published on 6/10/2023
Li Y, Gray A, Xue L, Farb MG, Ayalon N, Andersson C, Ko D, Benjamin EJ, Levy D, Vasan RS, Larson MG, Rong J, Xanthakis V, Liu C, Fetterman JL, Gopal DM. Metabolomic Profiles, Ideal Cardiovascular Health, and Risk of Heart Failure and Atrial Fibrillation: Insights From the Framingham Heart Study. J Am Heart Assoc. 2023 Jun 20; 12(12):e028022. PMID: 37301766.
Read at: PubMed
View 52 more publications: View full profile at BUMC